Literature DB >> 25623202

Viral hepatitis. HBV cure--can we pin our hopes on immunotherapy?

Hung-Chih Yang1, Jia-Horng Kao2.   

Abstract

Therapeutic vaccines are considered to be able to reverse the dysfunctional immune state of chronic hepatitis B and thus hold the promise for HBV cure. Martin et al. developed a novel adenovirus-based therapeutic vaccine TG1050 and demonstrated its induction of long-lasting antiviral CD8+ T-cell immunity in mouse models of HBV persistence.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25623202     DOI： 10.1038/nrgastro.2015.8

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

1.  The molecular basis of the failed immune response in chronic HBV: therapeutic implications.

Authors:  Mala K Maini; Anna Schurich
Journal:  J Hepatol       Date:  2010-01-07       Impact factor: 25.083

Review 2.  Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges.

Authors:  Marie-Louise Michel; Qiang Deng; Maryline Mancini-Bourgine
Journal:  J Hepatol       Date:  2011-01-14       Impact factor: 25.083

Review 3.  Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection.

Authors:  Antonio Bertoletti; Carlo Ferrari
Journal:  Gut       Date:  2011-12-09       Impact factor: 23.059

4.  Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

Authors:  Carolina Boni; Amalia Penna; Antonio Bertoletti; Vincenzo Lamonaca; Irene Rapti; Gabriele Missale; Massimo Pilli; Simona Urbani; Albertina Cavalli; Simona Cerioni; Ruggero Panebianco; Julian Jenkins; Carlo Ferrari
Journal:  J Hepatol       Date:  2003-10       Impact factor: 25.083

Review 5.  Immune surveillance by the liver.

Authors:  Craig N Jenne; Paul Kubes
Journal:  Nat Immunol       Date:  2013-09-18       Impact factor: 25.606

6.  Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

Authors:  Julie Lucifora; Yuchen Xia; Florian Reisinger; Ke Zhang; Daniela Stadler; Xiaoming Cheng; Martin F Sprinzl; Herwig Koppensteiner; Zuzanna Makowska; Tassilo Volz; Caroline Remouchamps; Wen-Min Chou; Wolfgang E Thasler; Norbert Hüser; David Durantel; T Jake Liang; Carsten Münk; Markus H Heim; Jeffrey L Browning; Emmanuel Dejardin; Maura Dandri; Michael Schindler; Mathias Heikenwalder; Ulrike Protzer
Journal:  Science       Date:  2014-02-20       Impact factor: 47.728

Review 7.  Improving clinical outcomes of chronic hepatitis B virus infection.

Authors:  Tung-Hung Su; Jia-Horng Kao
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-09-22       Impact factor: 3.869

8.  Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).

Authors:  Qin Ning; Meifang Han; Yongtao Sun; Jiaji Jiang; Deming Tan; Jinlin Hou; Hong Tang; Jifang Sheng; Mianzhi Zhao
Journal:  J Hepatol       Date:  2014-06-07       Impact factor: 25.083

9.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.

Authors:  Su-Ru Lin; Hung-Chih Yang; Yi-Ting Kuo; Chun-Jen Liu; Ta-Yu Yang; Ku-Chun Sung; You-Yu Lin; Hurng-Yi Wang; Chih-Chiang Wang; Yueh-Chi Shen; Fang-Yi Wu; Jia-Horng Kao; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-19       Impact factor: 10.183

10.  TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.

Authors:  Perrine Martin; Clarisse Dubois; Emilie Jacquier; Sarah Dion; Maryline Mancini-Bourgine; Ophélie Godon; Roland Kratzer; Karine Lelu-Santolaria; Alexei Evlachev; Jean-François Meritet; Yasmin Schlesinger; Dominique Villeval; Jean-Marc Strub; Alain Van Dorsselaer; Jean-Baptiste Marchand; Michel Geist; Renée Brandely; Annie Findeli; Houda Boukhebza; Thierry Menguy; Nathalie Silvestre; Marie-Louise Michel; Geneviève Inchauspé
Journal:  Gut       Date:  2014-11-26       Impact factor: 23.059
  10 in total
  6 in total

1.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 2.  Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection.

Authors:  Zhimin Guo; Thomas King
Journal:  Int J Mol Sci       Date:  2015-08-18       Impact factor: 5.923

3.  Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice.

Authors:  Lei Ye; Fangming Kan; Tao Yan; Jiaqi Cao; Leiliang Zhang; Zhijian Wu; Wuping Li
Journal:  Sci Rep       Date:  2017-06-20       Impact factor: 4.379

Review 4.  Elimination of Hepatitis B: Is It a Mission Possible?

Authors:  Tai-Chung Tseng; Jia-Horng Kao
Journal:  BMC Med       Date:  2017-03-15       Impact factor: 8.775

5.  Effect of adefovir dipivoxil on T cell immune function in the treatment of chronic hepatitis B and hepatocirrhosis.

Authors:  Liting Tian; Qilin Fu; Fu Huang
Journal:  Exp Ther Med       Date:  2016-08-29       Impact factor: 2.447

6.  Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates.

Authors:  Xuefeng Zhang; Jing Wang; Jing Lu; Rongrong Li; Shuli Zhao
Journal:  Virol J       Date:  2018-07-24       Impact factor: 4.099
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.